creators_name: Ding, C
creators_name: Jones, G
creators_id: chding@utas.edu.au
creators_id: 
type: article
datestamp: 2008-03-14 00:23:06
lastmod: 2008-07-18 10:41:17
metadata_visibility: show
title: Lumiracoxib (Novartis)
ispublished: pub
subjects: 320503
full_text_status: public
abstract: Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
date: 2002
date_type: published
publication: IDrugs
volume: 5
number: 12
pagerange: 1168-1172
refereed: TRUE
issn: 1369-7056
official_url: http://www.biomedcentral.com/1369-7056/5?issue=12
citation: Ding, C and Jones, G (2002) Lumiracoxib (Novartis). IDrugs, 5 (12). pp. 1168-1172. ISSN 1369-7056
document_url: http://eprints.utas.edu.au/3523/1/lumiracoxib.pdf